TY - JOUR
T1 - Immunogenicity of two doses of yeast recombinant hepatitis B vaccine in healthy older adults
AU - Gellin, Bruce G.
AU - Greenberg, Richard N.
AU - Hart, Richard H.
AU - Bertino, Joseph S.
AU - Stein, David H.
AU - Deloria, Maria A.
AU - Clements-Mann, Mary Lou
PY - 1997
Y1 - 1997
N2 - To determine the immunogenicity of two doses of yeast recombinant hepatitis B virus (HBV) vaccine containing surface (S) protein, an open- label, multicenter trial was conducted in 199 healthy HRV-seronegative adults ≤40 years old. Volunteers were randomly assigned to 1 of 5 groups to receive a total of three 10-μg doses, at 0, 1, and 6 months, or a total of two doses of 20 μg and 10 μg, 20 μg and 20 μg, 40 μg and 10 μg, or 40 μg and 20 μg at 0 and 6 months. The 40-μ/20-μg regimen elicited the highest rate of seroprotection (96.2%), with a geometric mean titer of antibody against the S protein of 369 mIU/mL, not significantly different from the 536 mIU/mL achieved with three doses. These results suggest that a two-dose regimen can achieve seroprotection similar to that of the three-dose regimen. Whether a shorter interval can be used or a booster dose will be needed later to confer durable immunity are unknown.
AB - To determine the immunogenicity of two doses of yeast recombinant hepatitis B virus (HBV) vaccine containing surface (S) protein, an open- label, multicenter trial was conducted in 199 healthy HRV-seronegative adults ≤40 years old. Volunteers were randomly assigned to 1 of 5 groups to receive a total of three 10-μg doses, at 0, 1, and 6 months, or a total of two doses of 20 μg and 10 μg, 20 μg and 20 μg, 40 μg and 10 μg, or 40 μg and 20 μg at 0 and 6 months. The 40-μ/20-μg regimen elicited the highest rate of seroprotection (96.2%), with a geometric mean titer of antibody against the S protein of 369 mIU/mL, not significantly different from the 536 mIU/mL achieved with three doses. These results suggest that a two-dose regimen can achieve seroprotection similar to that of the three-dose regimen. Whether a shorter interval can be used or a booster dose will be needed later to confer durable immunity are unknown.
UR - http://www.scopus.com/inward/record.url?scp=0031007432&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031007432&partnerID=8YFLogxK
U2 - 10.1086/516485
DO - 10.1086/516485
M3 - Article
C2 - 9180192
AN - SCOPUS:0031007432
SN - 0022-1899
VL - 175
SP - 1494
EP - 1497
JO - Journal of Infectious Diseases
JF - Journal of Infectious Diseases
IS - 6
ER -